Ki20227
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β) . Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction[1].
Product Specifications
CAS Number
623142-96-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Fms; c-Kit; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Ki20227.html
Concentration
10mM
Purity
99.51
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C=C1OC)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC(C)C4=NC=CS4
Molecular Formula
C24H24N4O5S
Molecular Weight
480.54
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ZFYVE20 sgRNA CRISPR Lentivector (Human) (Target 1)
Sheep Sjoegren Syndrome Nuclear Autoantigen 1 (SSNA1) ELISA Kit
Sheep Sjoegren Syndrome Nuclear Autoantigen 1 (SSNA1) ELISA Kit
Sheep Sjoegren Syndrome Nuclear Autoantigen 1 (SSNA1) ELISA Kit
Sheep Sjoegren Syndrome Nuclear Autoantigen 1 (SSNA1) ELISA Kit
